Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Alzheimer's & Dementia

• Publication date

  2013-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jalz.2011.11.005PMID 23110864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

  2011cited by this paper
• Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.

  2011cited by this paper
• Effects of memantine and donepezil on cortical and hippocampal acetylcholine levels and object recognition memory in rats.

  2011cited by this paper
• A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

  2010cited by this paper
• Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26‐week, open‐label, prospective trial (Study ENA713B US32)

  2010cited by this paper
• Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

  2009cited by this paper
• Cholinesterase inhibitors and beyond.

  2009cited by this paper
• Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

  2009cited by this paper
• P4‐334: Combination of memantine and donepezil reverses cognitive deficits in transgenic mice with both amyloid‐beta plaques and neurofibrillary tangles

  2009cited by this paper
• Steady-State Pharmacokinetics of Rivastigmine in Patients with Mild to Moderate Alzheimer’s Disease Not Affected by Co-Administration of Memantine

  2008cited by this paper
• Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

  2008cited by this paper
• Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

  2008influential reference
• Alzheimer's Disease Neuroimaging Initiative

  2008cited by this paper
• Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease

  2007cited by this paper
• Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials

  2007cited by this paper
• Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer’s Disease Treated with Rivastigmine

  2007cited by this paper
• Realistic expectations for treatment success in Alzheimer's disease.

  2006cited by this paper
• Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment

  2006cited by this paper
• Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

  2006cited by this paper
• Memantine for dementia.

  2006cited by this paper
• A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil: An Exploratory Reanalysis

  2006cited by this paper
• Memantine for dementia.

  2005cited by this paper
• Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

  2005cited by this paper
• Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

  2005cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004cited by this paper
• Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil

  2004cited by this paper
• Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

  2003cited by this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999cited by this paper

• Control analysis of deep brain stimulation and optogenetics for Alzheimer’s disease under the computational cortex model

  2025cites this paper
• Concurrent Quantification of Memantine and Donepezil via RP-UPLC with Stability Indicating Feature: Method Development and Validation

  2024cites this paper
• Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers

  2023cites this paper
• Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact

  2023cites this paper
• Antidementia Medication Use in Nursing Home Residents

  2023cites this paper
• Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

  2023cites this paper
• Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.

  2023cites this paper
• [Russian experience in using a combination of fixed doses of donepezil and memantine in the treatment of Alzheimer's disease as an observational non-interventional multicenter program].

  2023cites this paper
• Polypharmacy in Older Adults with Alzheimer’s Disease

  2022cites this paper
• Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: a potential treatment

  2022cites this paper
• Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1–42 rat model of Alzheimer’s disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway

  2021cites this paper
• A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer’s Disease

  2021cites this paper
• Cognitive Enhancers

  2021cites this paper
• Anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's disease: Nexus of cholinergic and nerve growth factor dysfunction.

  2021cites this paper
• Dementia

  2021cites this paper
• Pharmacological drug strategies in Alzheimer's Disease

  2021cites this paper
• Acetylcholinesterase inhibition, molecular docking and ADME prediction studies of new dihydrofuran-piperazine hybrid compounds

  2021cites this paper
• Mesenchymal stem cell therapies for Alzheimer’s disease: preclinical studies

  2021cites this paper
• Levistolide A Attenuates Alzheimer’s Pathology Through Activation of the PPARγ Pathway

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach

  2020cites this paper
• Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs

  2020cites this paper
• Anti-dementia Medications: Specific Agents

  2020cites this paper
• Synthesis, characterization, acetylcholinesterase inhibition, and molecular docking studies of new piperazine substituted dihydrofuran compounds

  2020cites this paper
• Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis

  2020cites this paper
• Kihito, a Traditional Japanese Kampo Medicine, Improves Cognitive Function in Alzheimer's Disease Patients

  2019cites this paper
• Treating Alzheimer’s Disease : Combine or Fail ?

  2019cites this paper
• Current and Future Treatments in Alzheimer's Disease

  2019cites this paper
• N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists

  2019cites this paper
• Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer’s Disease Clinical Trials: Potential for Confounding by Indication

  2019cites this paper
• The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

  2019cites this paper
• Amyloid Peptide Scaffolds Coordinate with Alzheimer's Disease Drugs.

  2019cites this paper
• Cholinesterase Inhibitors for Alzheimer Disease: Multitargeting Strategy based on Anti-Alzheimer's Drugs Repositioning.

  2019cites this paper
• Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017.

  2019cites this paper
• Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)

  2019cites this paper
• USING MULTIMODAL IMAGING TO EXAMINE CLINICAL AND COGNITIVE CORRELATES OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE

  2018cites this paper
• Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region

  2018cites this paper
• A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease

  2018cites this paper
• Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials

  2018cites this paper
• An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease

  2018cites this paper
• Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.

  2017cites this paper
• Therapeutic implication of autophagy in neurodegenerative diseases

  2017cites this paper
• [Memantine: from the original brand to generics].

  2017cites this paper
• Lithium and memantine improve spatial memory impairment and neuroinflammation induced by &bgr;‐amyloid 1–42 oligomers in rats

  2017cites this paper
• Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

  2017cites this paper
• Development of Nasal Lipid Nanocarriers Containing Curcumin for Brain Targeting

  2017cites this paper
• Oxoisoaporphine alkaloid derivative 8‐1 reduces A&bgr;1‐42 secretion and toxicity in human cell and Caenorhabditis elegans models of Alzheimer's disease

  2017cites this paper
• Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment

  2017cites this paper
• Novel conjugates of tacrine with 1,2,4,-thiadiazole as highly effective cholinesterase inhibitors, blockers of NMDA receptors, and antioxidants

  2017cites this paper
• Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment.

  2017cites this paper
• Nanotechnology‐based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

  2017cites this paper
• Computational and Experimental Approaches in Multi-Target Pharmacology

  2017cites this paper
• Effectiveness of cognition-focused interventions in activities of daily living performance in people with dementia: A systematic review

  2017cites this paper
• Effects of Choline Alfoscerate and Memantine on Memory Improvement of Scopolamine-induced Memory Impairment animal Model of Alzheimer’s Disease

  2017cites this paper
• Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease

  2017cites this paper
• Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β-Amyloid Cellular Pathologies through a Metal-Dependent Mechanism.

  2017cites this paper
• Dihydropyrimidine-thiones and clioquinol synergize to target beta-amyloid cellular pathologies through a metal-dependent mechanism

  2017cites this paper
• An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

  2016cites this paper
• Design, synthesis and preliminary structure–activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives

  2016cites this paper
• A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease

  2016cites this paper
• Comparative Memory/Behavioral Symptoms of Alzheimer's disease: EOAD vs. LOAD

  2016influential citation
• Ligandos multidiana, una estrategia alternativa para el tratamiento de la enfermedad de Alzheimer

  2016cites this paper
• Adamantane - A Lead Structure for Drugs in Clinical Practice.

  2016cites this paper
• Tratamiento farmacológico específico en la Enfermedad de Alzheimer.

  2016cites this paper
• Is the Combination/Multi-target Therapy a New Promise for Alzheimer's Disease?

  2016cites this paper
• Memantin als Add-on-Medikation zur Acetylcholinesteraseinhibitor-Therapie bei Alzheimer-Demenz

  2016cites this paper
• How Do We Use Symptomatic Drugs to Treat Dementia

  2016cites this paper
• Tertiary amine derivatives of chlorochalcone as acetylcholinesterase (AChE) and buthylcholinesterase (BuChE) inhibitors: the influence of chlorine, alkyl amine side chain and α,β-unsaturated ketone group

  2016cites this paper
• Practical Pharmacology of Memantine

  2016cites this paper
• Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease

  2015cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• Recent advances and applications of metabolomics to investigate neurodegenerative diseases.

  2015cites this paper
• The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

  2015cites this paper
• Benefits and risks of add-on therapies for Alzheimer's disease.

  2015cites this paper
• Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US

  2015cites this paper
• Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study

  2015cites this paper
• Charting a path toward combination therapy for Alzheimer’s disease

  2015cites this paper
• Pharmacological interventions for cognitive decline in people with Down syndrome.

  2015cites this paper
• Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology

  2015cites this paper
• Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease

  2015cites this paper
• Is Memantine + Acetylcholinesterase Inhibitor Treatment Superior to Either Therapy Alone in Alzheimer's Disease?

  2014cites this paper
• Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal

  2014cites this paper
• Memantyna w łagodnych zaburzeniach poznawczych i otępieniu alzheimerowskim o nasileniu lekkim: przesłanki teoretyczne, badania kliniczne i rekomendacje stosowania

  2014cites this paper
• Metabolomics in the Study of Alzheimer's Disease

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies

  2014cites this paper
• Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms

  2014cites this paper
• Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease.

  2014cites this paper
• Retrospective Study on the Benefits of Combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: The MEMAGE Study

  2014cites this paper
• Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study

  2014cites this paper
• Multi-target Design Strategies in the Context of Alzheimer’s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs interacting with Receptors. Update 2014

  2014cites this paper
• New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy

  2014cites this paper
• Calidad de vida, cuidadores e intervención para la mejora de la salud en el envejecimiento

  2013cites this paper
• Declive cognitivo en la enfermedad de Alzheimer. Seguimiento de más de tres años de una muestra de pacientes

  2013influential citation
• [Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients].

  2013cites this paper
• Neuroprotective effects of donepezil against Aβ42‐induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK‐3β and nAChRs activity

  2013cites this paper
• Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach.

  2013cites this paper
• Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

  2013cites this paper
• The Bivalent Ligand Approach as a Tool for Improving the in vitro Anti‐Alzheimer Multitarget Profile of Dimebon

  2013cites this paper